Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

IL-6 and IL-8 secretion by human glioma cells proliferating after Gamma-knife irradiation ; Секреция IL-6 и IL-8 клетками глиобластом человека, пролиферирующими после облучения на аппарате Гамма-нож

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Contributors:
      The work was performed according to Government Order “Study of resistant tumor cells on glioblastoma cultures in the simulation of stereotactic radiosurgery of recurrent glioblastoma” at the FSBI “Granov Russian Research Center of Radiology & Surgical Technologies” (St. Petersburg, Russia).; Работа выполнена в рамках Госзадания «Изучение резистентных опухолевых клеток на культурах глиобластом при моделировании стереотаксической радиохирургии рецидивирующей глиобластомы».
    • Publication Information:
      SPb RAACI
    • Publication Date:
      2023
    • Collection:
      Medical Immunology (E-Journal) / Медицинская иммунология
    • Abstract:
      One of the modern methods of treating patients with primary and recurrent brain tumors is radiosurgical irradiation using Gamma Knife, which allows therapeutic doses to be delivered to tumors not exceeding 2.5 cm in diameter in 1–2 sessions. Tumor cells on the periphery of this tissue volume that receive lower radiation doses can resume proliferation and serve as a source of recurrence. The increase of radiation dose may cause necroses formation and a worsening prognosis. The properties of glioblastoma cells that survive and resume proliferation long after stereotactic irradiation are still poorly known. The aim of the work was to evaluate the expression of IL-6 and IL-8 by glioblastoma A172, R1, T2, and T98G cell lines that resumed proliferation after sublethal Gamma Knife irradiation. Cells were irradiated once at doses ranging from 6 to 16 Gy, and then cultured for 40 days. Cell number was counted weekly; lethal and sublethal irradiation doses for each glioblastoma cell line were determined. In cultures descendant from proliferation of single most resistant cells, the level of IL-6 and IL-8 secretion after 96 hours cultivation (ng/1000 cells) was determined by ELISA. The cells of all four glioblastoma lines secreted IL-6 and IL-8 into culture medium. The highest production of cytokines, never before demonstrated for glioblastomas, was discovered in R1 cells. Glioblastoma T2 also had high interleukin production levels. In contrast to these lines, glioblastoma A172 (highly sensitive to the action of cytostatic drugs and radiation) secreted IL-6 at 30 times lower level than R1 cells. Glioblastoma T98G (highly resistant to the action of cytostatic drugs and radiation) also exhibited low interleukins production level. R1, T2, and T98G glioblastoma cells that resumed proliferation after irradiation had increased secretion of IL-6 and, to a lesser extent, IL-8. The dependence of cytokine production increase on irradiation dose for these cells was not linear. In contrast, A172 cells reduced IL-6 and IL-8 secretion ...
    • File Description:
      application/pdf
    • Relation:
      https://www.mimmun.ru/mimmun/article/view/2717/1695; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11125; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11126; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11127; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11132; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11133; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11134; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11136; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11137; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11138; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11139; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2717/11172; Brat D.J., Bellail A.C., Meir E.G.V. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol., 2005, Vol. 7, no. 2, pp. 122-133.; Bunevicius A., Radziunas A., Tamasauskas S., Tamasauskas A., Laws E.R., Iervasi G., Bunevicius R., Deltuva V. Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients. J. Neurooncol., 2018, Vol. 138, no. 2, pp. 351-358.; Canazza A., Calatozzolo C., Fumagalli L., Bergantin A., Ghielmetti F., Fariselli L., Croci D., Salmaggi A., Ciusani E. Increased migration of a human glioma cell line after in vitro CyberKnife irradiation. Cancer Biol. Ther., 2011, Vol. 12, no. 7, pp. 629-633.; Christofides A., Kosmopoulos M., Piperi C. Pathophysiological mechanisms regulated by cytokines in gliomas. Cytokine, 2015, Vol. 71, no. 2, pp. 377-384.; Ghandadi M., Sahebkar A. Interleukin-6: a critical cytokine in cancer multidrug resistance. Curr. Pharm. Des., 2016, Vol. 22, no. 5, pp. 518-526.; Kosmopoulos M., Christofides A., Drekolias D., Zavras P.D., Gargalionis A.N., Piperi C. Critical role of IL-8 targeting in gliomas. Curr. Med. Chem., 2018, Vol. 25, no. 17, pp. 1954-1967.; Niu N., Yao J., Bast R.C., Sood A.K., Liu J. IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming. Oncogenesis, 2021, Vol. 10, no. 9, pp. 65-72.; Pinevich A.A., Bode I.I., Vartanyan N.L., Kiseleva L.N., Kartashev A.V., Samoilovich M.P. Temozolomideresistant human T2 and T98G glioblastoma cells. Cell Tiss. Biol., 2022, Vol. 16, no. 4, pp. 126-140.; Pinevich A.A., Vartanyan N.L., Kartashev A.V., Kiseleva L.N., Smirnov I.V., Sidorova Z.U., Svitina S.P., Samoilovich M.P. Growth and molecular characteristics of temozolomide-resistant human A172 and R1 glioblastoma cells. Cytology, Vol. 65, no. 2, pp. 131-145. (In Russ.); Raskova M., Lacina L., Kejík Z., Venhauerova A., Skalickova M., Kolar M., Jakubek M., Rosel D., Smetana K. Jr., Brabek J. The role of IL-6 in cancer cell invasiveness and metastasis – overview and therapeutic opportunities. Cells, 2022, Vol. 11, no. 22, 3698. doi:10.3390/cells11223698.; Rolhion C., Penault-Llorca F., Kemeny J.L., Lemaire J.J., Jullien C., Labit-Bouvier C., Finat-Duclos F., Verrelle P. Interleukin-6 overexpression as a marker of malignancy in human gliomas. J. Neurosurg., 2001, Vol. 94, no. 1, pp. 97-101.; Sharma I., Singh A., Fouzia Siraj F., Saxena S. IL-8/CXCR1/2 signalling promotes tumor cell proliferation, invasion and vascular mimicry in glioblastoma. J. Biomed. Sci., 2018, Vol. 25, no. 1, 62. doi:10.1186/s12929-018-0464-y.; Shrivastava R., Gandhi P., Gothalwal R. The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions. Clin. Transl. Oncol., 2022, Vol. 24, no. 9, pp. 1702-1714.; Wang H., Lathia J.D., Wu Q., Wang J., Li Z., Heddleston J.M., Eyler C.E., Elderbroom J., Gallagher J., Schuschu J., MacSwords J., Cao Y., McLendon R.E., Wang X.F., Hjelmeland A.B., Rich J.N. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells, 2009, Vol. 27, no. 10, pp. 2393-2404.; Yuhas Y., Ashkenazi S., Berent E., Weizman A. Immunomodulatory activity of ketamine in human astroglial A172 cells: possible relevance to its rapid antidepressant activity. J. Neuroimmunol., 2015, Vol. 282, pp. 33-38.; https://www.mimmun.ru/mimmun/article/view/2717
    • Accession Number:
      10.15789/1563-0625-IAI-2717
    • Online Access:
      https://www.mimmun.ru/mimmun/article/view/2717
      https://doi.org/10.15789/1563-0625-IAI-2717
    • Rights:
      Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access).
    • Accession Number:
      edsbas.F1CEA1D4